MAIA Biotechnology, Inc. MAIA
MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2
‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting
and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia.
In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101,
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — | — |
| R&D | $453.7K | $10.0M | $11.1M | $8.9M | $3.5M | — |
| SG&A | $9.7M | $6.9M | $9.1M | $6.1M | $4.3M | — |
| Total operating expenses | $24.3M | $17.0M | $20.2M | $16.2M | $7.8M | — |
| Operating income | -$24.3M | -$17.0M | -$20.2M | -$16.2M | -$7.8M | — |
| Interest expense | — | $57 | $6.9K | $7.0K | $827.5K | — |
| Pre-tax income | -$22.4M | -$23.3M | -$19.8M | -$15.8M | -$12.6M | — |
| Income tax | $2.0K | $2.0K | — | — | — | — |
| Net income | -$22.4M | -$23.3M | -$19.8M | -$15.8M | -$12.6M | — |
| EPS, basic | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 | — |
| EPS, diluted | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 | — |
| Shares, diluted (wtd. avg.) | $32.1M | $22.2M | $13.3M | $9.3M | $5.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $0 | $11.0M | $10.6M | $663.5K |
| Total current assets | $9.7M | $10.2M | $7.6M | $11.8M | $10.7M | — |
| Total assets | $9.7M | $10.2M | $7.6M | $12.0M | $11.3M | — |
| Accounts payable | $2.0M | $1.5M | $1.6M | $1.2M | $960.4K | — |
| Total current liabilities | $5.8M | $3.8M | $4.9M | $3.3M | $2.1M | — |
| Total liabilities | $7.3M | $6.5M | $7.1M | $3.5M | $2.1M | — |
| Retained earnings | -$109.6M | -$87.2M | -$64.0M | -$44.2M | -$28.4M | — |
| Total equity | $2.4M | $3.6M | $477.5K | $8.5M | $9.2M | -$1.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.8M | -$15.7M | -$13.1M | -$12.1M | -$4.1M | — |
| Stock-based compensation | $2.6M | $1.9M | $3.1M | $2.3M | $2.7M | — |
| Financing cash flow | $17.9M | $18.2M | $9.3M | $12.5M | $14.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012088.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |